chronic kidney disease – Page 4

Semaglutide’s Impact on Cardiovascular Outcomes Across Chronic Kidney Disease Stages in Type 2 Diabetes: Insights from the FLOW Trial

By MedXY 08/16/2025

The FLOW trial demonstrates that semaglutide significantly lowers cardiovascular risks and mortality in type 2 diabetes patients with chronic kidney disease, independently of CKD severity.

Diabetes & Endocrinology Nephrology news Specialties

Exploring Combined Finerenone and Empagliflozin Therapy in CKD and Type 2 Diabetes: Baseline Insights from the CONFIDENCE Trial

By MedXY 08/13/2025

The CONFIDENCE trial evaluates whether combining finerenone with empagliflozin more effectively reduces urine albumin-to-creatinine ratio in CKD patients with type 2 diabetes compared to monotherapy, based on baseline characteristics of 818 diverse participants.

Cardiology Clinical Updates Nephrology Neurology news Specialties

OPTIMAS Trial: Early vs. Delayed Anticoagulation in Acute Ischemic Stroke with Atrial Fibrillation and Chronic Kidney Disease

By MedXY 08/13/2025

The OPTIMAS trial shows that chronic kidney disease does not alter the safety or efficacy of early direct oral anticoagulant use after acute ischemic stroke with atrial fibrillation, supporting early initiation regardless of kidney status.

Clinical Updates Diabetes & Endocrinology Nephrology news Specialties

Dual Renal Protection: Finerenone Plus Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes

By MedXY 08/09/2025

Combining finerenone with empagliflozin provides superior reduction in albuminuria for patients with chronic kidney disease and type 2 diabetes, without increased adverse events.